Ardelyx (ARDX) EBIT (2013 - 2026)
Ardelyx's (ARDX) quarterly EBIT came in at -$32.8 million in Q1 2026, up 9.78% YoY from -$29.9 million in Q1 2025, and down 743.13% on a QoQ basis from $5.1 million in Q4 2025.
Ardelyx (ARDX) EBIT (2013 - 2026) Analysis & Trends
Ardelyx (ARDX) has 14 years of EBIT data on file, last reported at -$32.8 million in Q1 2026.
- Quarterly EBIT rose 9.78% year-over-year to -$32.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.4 million (up 5.55% YoY) and the FY2025 annual result came in at -$41.0 million, down 46.61% from the prior year.
- EBIT eased to -$32.8 million in Q1 2026, from $5.1 million in the prior quarter.
- In the past five years, EBIT ranged from a high of $12.1 million in Q4 2022 to a low of -$36.3 million in Q1 2025.
- A 5-year average of -$13.5 million and a median of -$16.6 million in 2023 frame the typical range for EBIT.
- Annual changes were most pronounced in 2022 — EBIT surged 134.43% — and 2023, when it slumped 330.47%.
- Tracing ARDX's EBIT over 5 years: stood at $12.1 million in 2022, then tumbled by 330.47% to -$28.0 million in 2023, then soared by 129.03% to $8.1 million in 2024, then tumbled by 37.24% to $5.1 million in 2025, then slumped by 743.13% to -$32.8 million in 2026.
- The last three EBIT figures came in at -$32.8 million (Q1 2026), $5.1 million (Q4 2025), and $4.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Ardelyx | 1.01 Bn | 729.71 Mn | 115.12 Mn | -12.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -12.43 Mn |
| Mar 31, 2026 | -32.79 Mn |
| Dec 31, 2025 | 5.10 Mn |
| Sep 30, 2025 | 4.67 Mn |
| Jun 30, 2025 | -14.40 Mn |
| Mar 31, 2025 | -36.35 Mn |
| Dec 31, 2024 | 8.13 Mn |
| Sep 30, 2024 | 2.23 Mn |
| Jun 30, 2024 | -13.63 Mn |
| Mar 31, 2024 | -24.68 Mn |
| Dec 31, 2023 | -27.99 Mn |
| Sep 30, 2023 | 7.40 Mn |
| Jun 30, 2023 | -16.62 Mn |
| Mar 31, 2023 | -26.06 Mn |
| Dec 31, 2022 | 12.14 Mn |
| Sep 30, 2022 | -21.88 Mn |
| Jun 30, 2022 | -26.22 Mn |
| Mar 31, 2022 | -27.81 Mn |
| Dec 31, 2021 | -35.27 Mn |
| Sep 30, 2021 | -42.24 Mn |